208 related articles for article (PubMed ID: 20067787)
1. A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis.
Lin KT; Lien JC; Chung CH; Kuo SC; Huang TF
Eur J Pharmacol; 2010 Mar; 630(1-3):53-60. PubMed ID: 20067787
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
Morais C; Gobe G; Johnson DW; Healy H
Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
Kalkunte S; Brard L; Granai CO; Swamy N
Angiogenesis; 2005; 8(4):349-60. PubMed ID: 16400520
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis.
Kou B; Ni J; Vatish M; Singer DR
Microcirculation; 2008 Apr; 15(3):251-67. PubMed ID: 18386220
[TBL] [Abstract][Full Text] [Related]
6. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
[TBL] [Abstract][Full Text] [Related]
7. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo.
Xiao D; Singh SV
Cancer Res; 2007 Mar; 67(5):2239-46. PubMed ID: 17332354
[TBL] [Abstract][Full Text] [Related]
8. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
9. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
11. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
[TBL] [Abstract][Full Text] [Related]
12. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets.
Vizán P; Sánchez-Tena S; Alcarraz-Vizán G; Soler M; Messeguer R; Pujol MD; Lee WN; Cascante M
Carcinogenesis; 2009 Jun; 30(6):946-52. PubMed ID: 19369582
[TBL] [Abstract][Full Text] [Related]
16. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.
Sun HL; Tsai AC; Pan SL; Ding Q; Yamaguchi H; Lin CN; Hung MC; Teng CM
Clin Cancer Res; 2009 Aug; 15(15):4904-14. PubMed ID: 19622586
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic efficacy of grape seed extract in endothelial cells.
Agarwal C; Singh RP; Dhanalakshmi S; Agarwal R
Oncol Rep; 2004 Mar; 11(3):681-5. PubMed ID: 14767522
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
Chintalapati M; Truax R; Stout R; Portier R; Losso JN
J Agric Food Chem; 2009 Jun; 57(12):5201-10. PubMed ID: 19476359
[TBL] [Abstract][Full Text] [Related]
20. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
